Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like the fact that he kept a bunch of shares instead of selling all.
Manny
CIGX,
General Counsel waited exactly 10 years to exercise,and exercised 100,000 shares at 1.12 on the LAST day the Option was available.He sold and surrendered 59,141 shares at current prices.He kept 40,859 shares from this exercise.
He only owned 1,199 shares before this.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8300301
Manny
CIGX,
General Counsel waited exactly 10 years to exercise,and exercised 100,000 shares at 1.12 on the LAST day the Option was available.He sold and surrendered 59,141 shares at current prices.He kept 40,859 shares from this exercise.
He only owned 1,199 shares before this.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8300301
Manny
I should sell first and ask questions later.I did sell some,but too stupid to sell all.
Is this S-8 filing yesterday for more shares for employee plans a hint that something bad is coming,or is this just a way for the Market Makers to screw the little guy on a bad down day?
Time will tell.
- Securities Registration: Employee Benefit Plan (S-8)
Print
Alert
As filed with the Securities and Exchange Commission on May 29, 2012
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
IBIO, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
2834
26-2797813
(State of Other Jurisdiction of
(Primary Standard Industrial
(I.R.S. Employer
Incorporation or Organization)
Classification Code Number)
Identification Number)
9 Innovation Way, Suite 100, Newark, Delaware 19711
(Address of Principal Executive Offices, including Zip Code)
2008 Omnibus Equity Incentive Plan of iBioPharma, Inc.
(Full title of the plan)
Robert B. Kay
Chief Executive Officer
9 Innovation Way, Suite 100
Newark, Delaware 19711
(302) 355-0650
(Name, Address and Telephone Number of Agent for Service)
with copies to:
Andrew Abramowitz, Esq.
Andrew Abramowitz, PLLC
565 Fifth Avenue
9 th Floor
New York, New York 10017
(212) 972-8883 (fax)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company x
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered
Amount to be
Registered (1)
Proposed
Maximum
Offering Price
Per Unit
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration
Fee
Common Stock
5,476,667
(2)
$
1.56
(3)
$
8,543,601
$
979.10
Common Stock
4,523,333
(4)
$
1.24
(5)
$
5,608,933
$
642.78
(1)
In the event of a stock split, stock dividend or similar transaction involving the Registrant’s common stock, $0.001 par value per share (“Common Stock”), the number of shares registered hereby shall automatically be adjusted in accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”).
(2)
Represents shares of Common Stock subject to outstanding awards under the 2008 Omnibus Equity Incentive Plan of iBioPharma, Inc. (the “Plan”). Subsequent to the adoption of the Plan, the Registrant’s corporate name was changed from iBioPharma, Inc. to iBio, Inc.
(3)
The registration fee has been calculated in accordance with Rule 457(h) under the Securities Act, based upon the weighted average exercise price under the outstanding awards.
(4)
Represents shares of Common Stock available for future issuance under the Plan.
(5)
The registration fee has been calculated in accordance with Rule 457(h) under the Securities Act, based upon the average of the high and low sales prices of the Registrant’s common stock, as reported on the NYSE Amex Market, on May 21, 2012.
PART I
The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428(b)(1).
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The following documents are incorporated herein by reference:
1. The Company’s Annual Report on Form 10-K for the year ended June 30, 2011 filed with the SEC on September 29, 2011.
2. The Company’s Definitive Proxy Statement on Schedule 14A filed on November 8, 2011.
3. The Company’s Quarterly Reports on Form 10-Q, for the quarter ended September 30, 2011 filed with the SEC on November 14, 2011, for the quarter ended December 31, 2011 filed with the SEC on February 14, 2012, and for the quarter ended March 31, 2012 filed with the SEC on May 15, 2012.
4. The Company’s Current Reports on Form 8-K filed on November 4, 2011, November 8, 2011, December 13, 2011, January 10, 2012 and January 26, 2012.
5. The description of the Company’s Common Stock that is contained in the Company’s Registration Statement on Form 8-A (File No. 001-35023), filed on December 29, 2010.
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
The Registrant’s Certificate of Incorporation will provide for indemnification of the Registrant’s officers and directors to the extent permitted by Delaware law, which generally permits indemnification for actions taken by officers or directors as the Registrant’s representatives if the officer or director acted in good faith and in a manner he or she reasonably believed to be in the best interest of the corporation.
As permitted under Delaware law, the Registrant’s By-laws contain a provision indemnifying directors against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by them in connection with an action, suit or proceeding if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of our company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
Number
Description
3.1
Certificate of Incorporation of iBio, Inc., filed as Exhibit 3.1 to iBio’s Registration Statement on Form 10 filed on July 11, 2008 and incorporated herein by reference.
3.2
Certificate of Amendment to Certificate of Incorporation of iBio, Inc., filed as Exhibit 3.1 to iBio’s Current Report on Form 8-K filed on December 15, 2010 and incorporated herein by reference.
3.3
Form of Bylaws of iBio, Inc., filed as Exhibit 3.2 to iBio’s Current Report on Form 8-K filed on August 14, 2009 and incorporated herein by reference.
4.1
Form of Common Stock Certificate of iBio, Inc., filed as Exhibit 4.1 to iBio’s Registration Statement on Form 10 filed on July 11, 2008 and incorporated herein by reference.
5.1
Opinion of Andrew Abramowitz, PLLC
23.1
Consent of J.H. Cohn LLP
23.2
Consent of Andrew Abramowitz, PLLC (included in Exhibit 5.1)
24.1
Power of Attorney (included in Part II of this registration statement)
99.1
2008 Omnibus Equity Incentive Plan of iBioPharma, Inc.
Item 9.
Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii) to include any material information with respect to the Plan not previously disclosed in the registration statement or any material change to such information in the registration statement;
Provided, however, that paragraphs 1(i), 1(ii) and 1(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions referenced in Item 6 of this Registration Statement, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newark, State of Delaware on May 29, 2012.
IBIO, INC.
By:
/s/ Robert B. Kay
Robert B. Kay
Chief Executive Officer
and Director
POWER OF ATTORNEY
We, the undersigned officers and directors of the Registrant, iBio, Inc., a Delaware corporation, hereby severally and individually constitute and appoint Robert B. Kay, Chief Executive Officer and Douglas Beck, CPA, Chief Financial Officer, and each of them, as true and lawful attorneys in fact for the undersigned, in any and all capacities, with full power of substitution, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys in fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys in fact, or any of them, may lawfully do or cause to be done by virtue of this appointment.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Robert B. Kay
Chief Executive Officer and Director
(Principal Executive Officer)
May 29, 2012
Robert B. Kay
/s/ Douglas Beck, CPA
Chief Financial Officer (Principal
Financial and Accounting Officer)
May 29, 2012
Douglas Beck, CPA
/s/ James T. Hill
Director
May 29, 2012
General James T. Hill (Ret.)
/s/ Glenn Chang
Director
May 29, 2012
Glenn Chang
/s/ John D. McKey, Jr.
Director
May 29, 2012
John D. McKey, Jr.
/s/ Philip K. Russell
Director
May 29, 2012
Philip K. Russell, M.D.
/s/ Arthur Y. Elliott
Director
May 29, 2012
Arthur Y. Elliott, Ph.D.
Jules A. Müsing
Director
May 29, 2012
Jules A. Müsing
VHC,
The last paragraph sounds the best.
"A big consideration for investors is what impact any additional settlement will have on the stock price of VirnetX. The recent settlement with Aastra led to a strong upward rally in VirnetX and the stock has held those gains to date. If a company like Mitel also settles, we could witness a similar reaction in the stock price. However, if any of the other defendants come to an agreement with VirnetX, the stock could reach new all-time highs. Looking at the timeline and considering management's recent comments, VirnetX is poised to take the next step in this legal battle. This appears to be an excellent near-term opportunity for investors."
Manny
SARA,
A nice vote of confidence by the Blackstone Group,a 10% owner,purchasing 800,000 shares at 6.25 in the recent offering.
They now control 4.8 million shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8294405
Manny
VHC,
Is giving 8,333 vesting shares to Directors and 12,500 options to buy shares at 29.9 , all to vest and be exercised on 5/24/2013.
Nice timing.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8293273
Manny
VHC-Is giving 8,333 vesting shares to Directors and 12,500 options to buy shares at 29.9 , all to vest and be exercised on 5/24/2013.
Nice timing.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8293273
Manny
VHC,
From IV:
09:46 EDT VHC
theflyonthewall.com: VirnetX initiated with a Buy at Gilford Securities (pre-open)
Target $65.
VHC,
From IV:
09:46 EDT VHC
theflyonthewall.com: VirnetX initiated with a Buy at Gilford Securities (pre-open)
Target $65.
VHC,
Posted on the IV board:
"Perfect Storm" - from beachnorwegian (who attended the ASM) on the Y board
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_V/threadview?m=te&bn=44556&tid=79906&mid=79906&tof=10&frt=2#79906
Hello everyone. That's my favorite quote from Kendall this year. He described VHC as a "once in a lifetime deal. I've never seen a perfect storm like this." And referring to the 6 remaining co-defendants, he said "We're going to get these guys licensed up. We're very confident. Things are going very well." He predicted major settlement activity this fall heading into the trial date and said the 6 co-defendants settling would only "jump-start" VHC into further success.
I was concerned that CSCO and AAPL's intransigence might have led Kendall to be more measured and restrained in his outlook, however time and time again throughout the ASM, he expressed confidence that it was only a matter of time before AAPL and everyone else conceded that VHC owns the "crown jewels".
I'm so glad I made the trek from Miami to attend my first VHC ASM and met DKitt, Floydrocks, and a host of non-posters along with company leaders Kendall and Victor Larson. As I'm sure other posters have made clear, Kendall was "extremely pleased" with the Markman calling the findings "fantastic results" and added "We got what we wanted". He again suggested that 90% of the company's value is still unrealized. "We look at ourselves and model ourselves after Qualcomm", adding, "You don't want to face these (VHC's) patents if you're in court". He added, "These are not widget patents, these are foundational".
Kendall made a point of saying there'd be no more MSFT-like one-sum package settlements and said future deals would include on-going royalty payments. He also suggested that he'd be running VHC for years to come and I certainly got no indication whatsoever that he was hoping to exit the company anytime soon.
I'll leave you with this final quote from Kendall. "I can assure you your investment is in very good shape right now...Things are moving now".
Cheers everyone.
Rating :
Congratulations.
Looks like your 2 dollar post was the time to buy.
Stock is at 7.02,up 10% for the day.
Manny
It is a matter of allocating funds,since I am low on cash.
I have no idea if this is the right move or not.
I have definitely sold stock at bottoms in the past,just because I wanted to buy something else.
I have VASO on my Watchlist and will buy back on any significant news.
I still haven't sold my last 4100 shares at .23.(lol)
Manny
VASO,
For anyone looking to buy shares in VASO at .23,I am selling 4100,which is not currently being shown by the Market Makers.
They are showing .22 by .2459,and will buy my .23 shares to sell to you at .2459.
Manny
VASO,
For anyone looking to buy shares in VASO at .23,I am selling 4100,which is not currently being shown by the Market Makers.
They are showing .22 by .2459,and will buy my .23 shares to sell to you at .2459.
Manny
Major sale of 159,400 shares by CEO at 1.686 average price.
He still has 310,194 shares.
http://www.secform4.com/insider-trading/1373485.htm
I have no current position.
Manny
TSPT,
The company shows 59.21 million in cash in most recent quarter with 14.01 million outstanding shares.
Add 37.6 million in cash from recent share sale and add 4.5 million shares sold,you get 96.81 million dollars in cash,and 18.51 million shares.
96.81/18.51 gets you 5.23 dollars cash per share.
This is besides the potential revenue from their new sleep drug on the market,and the current 6.56 price is ridiculous.
Keep dreaming on 2 dollars.
Manny
You would probably get a ton of recommendations on Knight getting screwed.
I am one of their victims over the years.
I wish they lost 100 million.
Manny
Sorry,
I have no idea.
Manny
As soon as I heard that a record 132 million votes were made,I knew Phillip won it.
All those girls and ladies voting for Phillip.
Joshua didn't have a chance,but he will be more successful.
Manny
HDY,
These Insider purchases at .79 and .855 yesterday,might give people the confidence that things are happening,and bring this stock over a dollar shortly.
http://www.secform4.com/insider-trading/937136.htm
Manny
HDY,
These Insider purchases at .79 and .855 yesterday,might give people the confidence that things are happening,and bring this stock over a dollar shortly.
http://www.secform4.com/insider-trading/937136.htm
Manny
HDY,
Was yesterday 1.04 at it's high,and closed at .79.
It looks like Insiders like these prices,with a 30,740 share buy at .7911,and an 18,000 share buy at .855.
http://www.secform4.com/insider-trading/937136.htm
Bank of America is searching for an investor or a partner for HDY for its Guinea properties.
Looks like the Directors are confident of a deal,by buying at these prices.
Manny
HDY,
Was yesterday 1.04 at it's high,and closed at .79.
It looks like Insiders like these prices,with a 30,740 share buy at .7911,and an 18,000 share buy at .855.
http://www.secform4.com/insider-trading/937136.htm
Bank of America is searching for an investor or a partner for HDY for its Guinea properties.
Looks like the Directors are confident of a deal,by buying at these prices.
Manny
CIGX,
Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced today that it has completed its retail distribution of Anatabloc® at GNC, a leading global specialty retailer of health and wellness products. As of this week, Anatabloc® is now available at all of GNC's corporate stores, which includes approximately 2,922 locations in all fifty states, as well as the District of Columbia and Puerto Rico. The product is also available at GNC.com and anatabloc.com.
(Photo: http://photos.prnewswire.com/prnh/20120523/PH12327 )
(Photo: http://photos.prnewswire.com/prnh/20110830/PH59627 )
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
Anatabloc® was first offered to GNC customers on February 1, 2012, when the retailer began selling the product through GNC.com and on April 1 in select stores. After sales of Anatabloc® showed impressive growth in-store, GNC decided to expand distribution to all of its US-owned retail locations, completing the expansion this week.
Thomas Dowd, Executive Vice President, Chief Merchandising Officer & General Manager of GNC, commented, "Sales of Anatabloc®, both online and in our stores, have surpassed our expectations. In just over three months, Anatabloc® has become one of our fastest growing products, and by making Anatabloc® available in all of our corporate stores, we are taking steps to ensure that our customers have easy access to one of the products most highly in demand."
In support of the expansion, GNC on June 1, 2012 will begin using an advertisement poster of professional golfer and Anatabloc® Brand Ambassador, Fred Couples, prominently displayed on the front window of every GNC corporate store. Couples is a 32-year veteran of the PGA Tour, with over 50 professional tournament wins, including the Masters (1992). In addition, he has been twice named the PGA Tour Player of the Year (1991, 1992). The advertising campaign featuring Couples is expected to last two months.
David M. Dean, Vice President of Sales and Marketing for Star Scientific, Inc., stated, "GNC continues to be a valuable partner for Anatabloc® because of its reputation in the area of nutritional supplementation and its loyal customer base. We are very much looking forward to an ongoing relationship with GNC as we continue to expand the marketing and distribution of Anatabloc®."
Paul L. Perito, CEO and Chairman of Rock Creek Pharmaceuticals, Inc., further commented, "The recent notice of allowance for claims relating to the synthesis of anatabine ensures that we will be able to make available to GNC a product whose main ingredient has the benefit of being produced utilizing a process that will be covered by our patent."
Currently, more than half of GNC's 928 franchise stores have Anatabloc® on their shelves for in-store purchasing, and all franchise locations can order Anatabloc® for interested customers.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
Web: anatabloc.com l Facebook: www.facebook.com/Anatabloc
About GNCGNC Holdings, Inc., headquartered in Pittsburgh, PA, is a leading global specialty retailer of health and wellness products, including vitamins, minerals, and herbal supplement products, sports nutrition products and diet products, and trades on the New York Stock Exchange under the symbol "GNC."
As of March 31, 2012, GNC has more than 7,700 locations, of which more than 5,900 retail locations are in the United States (including 928 franchise and 2,146 Rite Aid franchise store-within-a-store locations) and franchise operations in 56 countries (including distribution centers where retail sales are made). The Company – which is dedicated to helping consumers Live Well – has a diversified, multi-channel business model and derives revenue from product sales through company-owned retail stores, domestic and international franchise activities, third party contract manufacturing, e-commerce and corporate partnerships. Its broad and deep product mix, which is focused on high-margin, premium, value-added nutritional products, is sold under GNC proprietary brands, including Mega Men®, Ultra Mega®, GNC Total Lean, Pro Performance® and Pro Performance® AMP, and under nationally recognized third party brands.
For more than 75 years, GNC has been committed to bringing people superior GNC brand products using only the highest quality ingredients, manufactured under the strictest quality controls. Managing every stage of the process - from formulation to retailing - allows GNC to guarantee quality, purity and potency of GNC products.
Web: GNC.com l Twitter: @GNCLiveWell l Facebook: facebook.com/GNCLiveWell
Contact:Talhia T. TuckVice President, Communications and Investor RelationsStar Scientific, Inc. (301) 654-8300ttuck@starscientific.com
SOURCE Star Scientific, Inc.
CIGX,
Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced today that it has completed its retail distribution of Anatabloc® at GNC, a leading global specialty retailer of health and wellness products. As of this week, Anatabloc® is now available at all of GNC's corporate stores, which includes approximately 2,922 locations in all fifty states, as well as the District of Columbia and Puerto Rico. The product is also available at GNC.com and anatabloc.com.
(Photo: http://photos.prnewswire.com/prnh/20120523/PH12327 )
(Photo: http://photos.prnewswire.com/prnh/20110830/PH59627 )
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
Anatabloc® was first offered to GNC customers on February 1, 2012, when the retailer began selling the product through GNC.com and on April 1 in select stores. After sales of Anatabloc® showed impressive growth in-store, GNC decided to expand distribution to all of its US-owned retail locations, completing the expansion this week.
Thomas Dowd, Executive Vice President, Chief Merchandising Officer & General Manager of GNC, commented, "Sales of Anatabloc®, both online and in our stores, have surpassed our expectations. In just over three months, Anatabloc® has become one of our fastest growing products, and by making Anatabloc® available in all of our corporate stores, we are taking steps to ensure that our customers have easy access to one of the products most highly in demand."
In support of the expansion, GNC on June 1, 2012 will begin using an advertisement poster of professional golfer and Anatabloc® Brand Ambassador, Fred Couples, prominently displayed on the front window of every GNC corporate store. Couples is a 32-year veteran of the PGA Tour, with over 50 professional tournament wins, including the Masters (1992). In addition, he has been twice named the PGA Tour Player of the Year (1991, 1992). The advertising campaign featuring Couples is expected to last two months.
David M. Dean, Vice President of Sales and Marketing for Star Scientific, Inc., stated, "GNC continues to be a valuable partner for Anatabloc® because of its reputation in the area of nutritional supplementation and its loyal customer base. We are very much looking forward to an ongoing relationship with GNC as we continue to expand the marketing and distribution of Anatabloc®."
Paul L. Perito, CEO and Chairman of Rock Creek Pharmaceuticals, Inc., further commented, "The recent notice of allowance for claims relating to the synthesis of anatabine ensures that we will be able to make available to GNC a product whose main ingredient has the benefit of being produced utilizing a process that will be covered by our patent."
Currently, more than half of GNC's 928 franchise stores have Anatabloc® on their shelves for in-store purchasing, and all franchise locations can order Anatabloc® for interested customers.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
Web: anatabloc.com l Facebook: www.facebook.com/Anatabloc
About GNCGNC Holdings, Inc., headquartered in Pittsburgh, PA, is a leading global specialty retailer of health and wellness products, including vitamins, minerals, and herbal supplement products, sports nutrition products and diet products, and trades on the New York Stock Exchange under the symbol "GNC."
As of March 31, 2012, GNC has more than 7,700 locations, of which more than 5,900 retail locations are in the United States (including 928 franchise and 2,146 Rite Aid franchise store-within-a-store locations) and franchise operations in 56 countries (including distribution centers where retail sales are made). The Company – which is dedicated to helping consumers Live Well – has a diversified, multi-channel business model and derives revenue from product sales through company-owned retail stores, domestic and international franchise activities, third party contract manufacturing, e-commerce and corporate partnerships. Its broad and deep product mix, which is focused on high-margin, premium, value-added nutritional products, is sold under GNC proprietary brands, including Mega Men®, Ultra Mega®, GNC Total Lean, Pro Performance® and Pro Performance® AMP, and under nationally recognized third party brands.
For more than 75 years, GNC has been committed to bringing people superior GNC brand products using only the highest quality ingredients, manufactured under the strictest quality controls. Managing every stage of the process - from formulation to retailing - allows GNC to guarantee quality, purity and potency of GNC products.
Web: GNC.com l Twitter: @GNCLiveWell l Facebook: facebook.com/GNCLiveWell
Contact:Talhia T. TuckVice President, Communications and Investor RelationsStar Scientific, Inc. (301) 654-8300ttuck@starscientific.com
SOURCE Star Scientific, Inc.
It's simple.
They gave Jessica a weak song,and gave Phillip a pretty good song.
Phillip will probably win.
I didn't vote for either.
I missed the excitement that Joshua brings.
I am looking forward to hearing Joshua again.He will probably make more money and have more fame than essica or Phillip.
Manny
CLSN,
Director buy 4520 shares at 1.77.He now owns 65,927 shares
http://www.secform4.com/insider-trading/749647.htm
Manny
I don't know what time Saturday Night Live is on the West Coast,but if it has not been on yet,you must watch it.
Mick Jagger is the host,singing ,and also with the Foo Fighters.
He is awesome.Never sounded better.
The show itself is very funny,and you get a mini concert from Mick.
I would love it if Steve Taylor leaves,Mick Jagger signs on.
I think Elise should watch Mick Jagger to see how to deliver a Rock and Roll song.
Manny
Anyone still in this stock?
This Market is really taking a drubbing lately,as am I.
I can't believe that Tang Capital took such a big stake at 9.,and this closed at 6.99.
I hope their new drug is selling well.
Manny
LWLG,
You can ask on the LWLG board.That's where the patent info was posted.
I have no idea what that thing is.
Manny
LWLG,
From a very sharp poster on IV who found this.
New Patent 11/666,319 was just allowed
http://www.scribd.com/doc/94045198/11666319noticeofallowance[/url]
Manny
AAPL,
Is moving higher.There is a lot of speculation that all that money unleashed from Facebook IPO will look for a place to invest,and AAPL might be one.of the beneficiaries.
Manny
SQNM
Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In ...
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Along with this week's publication, the Company announces that as of the week ended May 12, 2012, Sequenom CMM has processed more than 10,000 commercial MaterniT21 PLUS test samples in 2012.
The publication addresses the capability of the MaterniT21 PLUS LDT to accurately detect the presence of certain fetal trisomies in pregnant women carrying twins or triplets. The paper will appear in the journal's May issue and the full abstract can be found online at: http://onlinelibrary.wiley.com/doi/10.1002/pd.3892/abstract.
"The underlying biology and these positive study data provide evidence that this type of DNA-testing can be reliably employed as a clinical management option for women expecting twins or triplets who are at increased risk for fetal chromosome anomalies," said Allan Bombard, M.D., Laboratory Director for Sequenom Center for Molecular Medicine.
The published results are derived from the large international, multi-center study conducted at 27 prenatal diagnostic centers worldwide, with previous publications on trisomy 21 and trisomies 18 and 13 in Genetics in Medicine. Participating sites collected and processed maternal plasma samples from 4,664 pregnant women in the late first and early second trimester who were at increased risk for fetal aneuploidy. Blinded samples from pregnancies with trisomy 21, trisomy 18, and trisomy 13 as well as those with other abnormal karyotypes were tested.
In the same multi-center study, maternal plasma samples were tested from 25 twin and two triplet pregnancies. Of the twin pregnancies, there were no trisomies in 17 pregnancies (known as euploid), trisomy 21 in seven (two cases of trisomy 21 in both fetal twins, five cases of trisomy 21 in one fetal twin only), and trisomy 13 in one (in one fetal twin). There were two triplet pregnancies, neither of which had trisomies. The MaterniT21 PLUS technology correctly classified the eight twin pregnancies with trisomy 21 or trisomy 13, the 17 twin euploid pregnancies and both triplet euploid pregnancies.
"We know that, in the U.S., pregnant women carrying twins or higher multiples are becoming more common due to the use of assisted reproductive technologies and acknowledge that more of these women have increased risks for fetal aneuploidy, such as advanced maternal age," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc. "This published data provides valuable evidence to specialists that Sequenom CMM's MaterniT21 PLUS LDT can provide reliable detection of certain fetal trisomies in twins, just as in single pregnancies."
The research was led by Jacob Canick, PhD, and Glenn Palomaki, PhD, of the Division of Medical Screening and Special Testing in the Department of Pathology and Laboratory Medicine at Women & Infants Hospital and The Warren Alpert Medical School of Brown University. The study also included scientists at Sequenom Center for Molecular Medicine, San Diego, CA.
As of the week ended May 12, Sequenom CMM has processed more than 10,000 MaterniT21 PLUS tests in 2012. Due to the successful rate of adoption, the Company recently announced that it has increased its internal goal to 40,000 MaterniT21 PLUS tests billed in 2012, up from the original internal goal of 25,000 tests billed for the year. As of the last week in April, the 52-week run rate had increased to more than 45,000 tests.
The MaterniT21 PLUS LDT is available solely through Sequenom CMM as a testing service to physicians. To learn more about the test, please visit Sequenomcmm.com.
About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Sequenom CMM, LLCSequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists and maternal fetal medicine specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.
Forward-Looking StatementsExcept for the historical information contained herein, the matters set forth in this press release, including statements regarding the intended use for and capabilities of the MaterniT21 PLUS test, expectations regarding the future performance, utility, and impact of the test, the Company's goals for the number of MaterniT21 PLUS tests to be billed for 2012 and the 52-week run rate, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MaterniT21 PLUS LDT, reliance upon the collaborative efforts of other parties, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)
SOURCE Sequenom, Inc.
SQNM
Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In ...
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Along with this week's publication, the Company announces that as of the week ended May 12, 2012, Sequenom CMM has processed more than 10,000 commercial MaterniT21 PLUS test samples in 2012.
The publication addresses the capability of the MaterniT21 PLUS LDT to accurately detect the presence of certain fetal trisomies in pregnant women carrying twins or triplets. The paper will appear in the journal's May issue and the full abstract can be found online at: http://onlinelibrary.wiley.com/doi/10.1002/pd.3892/abstract.
"The underlying biology and these positive study data provide evidence that this type of DNA-testing can be reliably employed as a clinical management option for women expecting twins or triplets who are at increased risk for fetal chromosome anomalies," said Allan Bombard, M.D., Laboratory Director for Sequenom Center for Molecular Medicine.
The published results are derived from the large international, multi-center study conducted at 27 prenatal diagnostic centers worldwide, with previous publications on trisomy 21 and trisomies 18 and 13 in Genetics in Medicine. Participating sites collected and processed maternal plasma samples from 4,664 pregnant women in the late first and early second trimester who were at increased risk for fetal aneuploidy. Blinded samples from pregnancies with trisomy 21, trisomy 18, and trisomy 13 as well as those with other abnormal karyotypes were tested.
In the same multi-center study, maternal plasma samples were tested from 25 twin and two triplet pregnancies. Of the twin pregnancies, there were no trisomies in 17 pregnancies (known as euploid), trisomy 21 in seven (two cases of trisomy 21 in both fetal twins, five cases of trisomy 21 in one fetal twin only), and trisomy 13 in one (in one fetal twin). There were two triplet pregnancies, neither of which had trisomies. The MaterniT21 PLUS technology correctly classified the eight twin pregnancies with trisomy 21 or trisomy 13, the 17 twin euploid pregnancies and both triplet euploid pregnancies.
"We know that, in the U.S., pregnant women carrying twins or higher multiples are becoming more common due to the use of assisted reproductive technologies and acknowledge that more of these women have increased risks for fetal aneuploidy, such as advanced maternal age," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc. "This published data provides valuable evidence to specialists that Sequenom CMM's MaterniT21 PLUS LDT can provide reliable detection of certain fetal trisomies in twins, just as in single pregnancies."
The research was led by Jacob Canick, PhD, and Glenn Palomaki, PhD, of the Division of Medical Screening and Special Testing in the Department of Pathology and Laboratory Medicine at Women & Infants Hospital and The Warren Alpert Medical School of Brown University. The study also included scientists at Sequenom Center for Molecular Medicine, San Diego, CA.
As of the week ended May 12, Sequenom CMM has processed more than 10,000 MaterniT21 PLUS tests in 2012. Due to the successful rate of adoption, the Company recently announced that it has increased its internal goal to 40,000 MaterniT21 PLUS tests billed in 2012, up from the original internal goal of 25,000 tests billed for the year. As of the last week in April, the 52-week run rate had increased to more than 45,000 tests.
The MaterniT21 PLUS LDT is available solely through Sequenom CMM as a testing service to physicians. To learn more about the test, please visit Sequenomcmm.com.
About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Sequenom CMM, LLCSequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists and maternal fetal medicine specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.
Forward-Looking StatementsExcept for the historical information contained herein, the matters set forth in this press release, including statements regarding the intended use for and capabilities of the MaterniT21 PLUS test, expectations regarding the future performance, utility, and impact of the test, the Company's goals for the number of MaterniT21 PLUS tests to be billed for 2012 and the 52-week run rate, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MaterniT21 PLUS LDT, reliance upon the collaborative efforts of other parties, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)
SOURCE Sequenom, Inc.
Once again America has proven that the winner is not necessarily going to be the most successful artist.
It happened with Jennifer Hudson,Adam Lampert and Daughtry.
I think Joshua is a great singer,a real professional,and when he brought his mother to the stage on his farewell song ,"It's a man's world",might have given some people who didn't vote for him some regrets.
I can't wait to hear Joshua and his future album.
I think Jessica will also be very successful.
It "pains" me to watch Phillip Phillips sing.
My 25 votes for Joshua weren't enough.(lol).
Manny
CLSN,
Director buys 5,000 shares at 1.93.He now owns 21,000 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8274155
Manny
VHC,
From a poster on IV
Cowan Report follow-up
After reading the Cowan report for the 4th time, I wanted to highlite several comments contained in the report. Obviously Cowan has been talking to VHC management and have become our path to getting management feedback on the ongoing negotiations. Here are 4 quotes from the report:
'Post the agreement’s signing we have spoken with VHC
management several times."
Per the company, the remaining defendants are participating in a formal, federally-mandated mediation process (the Aastra settlement talks also took place under the federal mediation umbrella)."
"management’s contention that defendants have become more serious about settling post-Markman"
"Management has also acknowledged the recent Markman ruling has generated an uptick in “non-party interest” "
These comments are important in that they convey that parties are negotiating, not waiting for the trial and raise the prospects of settlements. The fact that the parties are "more serious" indicates that they believe the Markman was in VHC's favor.
PSGY,
Princeton Security Technologies (OTC-BB: PSGY) Announces Q1
Princeton Security Technologies, Inc. (OTCBB: PSGY), a leading supplier of X-ray and Gamma-ray Detectors, Spectroscopy systems and Radioactive Isotope Identifier Devices (RIID) through its wholly-owned subsidiary Princeton Gamma-Tech Instruments Inc. (PGT), announced first quarter results for the quarter ending March 31, 2012.
PSGY's sales for the first quarter in 2012 grew by 74 percent to over $1.5 Million from the approximate $870,000 for the same period in 2011. This sales growth caused increased Gross Profit amounting to more than $855,000 for Q1. The Gross Profit in the first quarter was 86 percent more than the approximate $459,000 from the previous year.
The net profit consequently increased by 38 percent to $241,391 and the net profit per share of common stock also increased to $.02 for the quarter ending March 31, 2012.
The company expects continued growth as the demand for Radioactive Isotope Identifier products increases.
About Princeton Security Technologies Inc.:
Princeton Security Technologies, through its wholly owned subsidiary, Princeton Gamma-Tech Instruments, Inc (PGT), is a supplier of X-ray and Gamma-ray Detectors and Spectroscopy systems, and Radioactive Radioisotope Identifier products. The Company serves a broad customer base in scientific research, industrial materials analysis, and Homeland Security.
Princeton Gamma Tech Instruments has brought leadership and technical innovation to the semiconductor gamma and X-ray detection field for over 35 years. Recent accomplishments include a state-of-the-art isotope identification technology for fixed and portable applications and a scalable software control application for the rapid deployment of multiple sensors. The corporation markets its off the shelf products and services directly, as well as via a distributor network domestically and internationally.
Further information regarding both companies can be found at www.PGT.com.
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Contact:
Trupti Mehta
tel.#: (609) 924 7310
e-mail: Email Contact
VRNG,
S-8 registration.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8273546
This Registration Statement registers 14,139,342 shares of our common stock that may be issued and sold under our Amended and Restated 2006 Stock Option Plan, as amended (the “Plan”). This Registration Statement also registers the reoffer and sale, in accordance with Section C of the General Instructions to the Form S-8, of 2,517,167 shares of common stock acquired prior to the date hereof pursuant to the Plan by the Selling Stockholders set forth in this prospectus.